Zilovertamab vedotin is an Antibody-drug conjugate (ADC) comprising an anti-ROR1 monoclonal antibody (UC-961), a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker (mc-vc-PAB), and a monomethyl auristatin E (MMAE) cytotoxin.
Zilovertamab vedotin is an Antibody-drug conjugate (ADC) comprising an anti-ROR1 monoclonal antibody (UC-961), a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker (mc-vc-PAB), and a monomethyl auristatin E (MMAE) cytotoxin.
No indication information available.
No associated conditions information available.
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2025/03/24 | Phase 2 | Recruiting | |||
2024/12/05 | Phase 3 | Recruiting | |||
2024/05/01 | Phase 1 | Recruiting | |||
2022/10/03 | Phase 1 | Active, not recruiting | |||
2022/07/14 | Phase 2 | Recruiting | |||
2022/06/06 | Phase 2 | Active, not recruiting | |||
2021/12/01 | Phase 2 | Recruiting | |||
2020/08/07 | Phase 2 | Terminated | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | ||
2019/02/06 | Phase 1 | Completed | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
Product Name | Manufacturer | Route | Strength | Approved | NDC Code |
---|
No FDA products found for this drug
Medicine Name | EMA Number | Auth. Holder | Country | Drug Type | Status | Issued | Opinion | Revision |
---|
No EMA products found for this drug
Product Name | Manufacturer | Dosage Form | Strength | Approved | Approval No. |
---|
No Singapore products found for this drug
Product Name | Approval No. | Manufacturer | Dosage Form | Trade Name | Strength | Type | Status | Date | Import |
---|
No China products found for this drug
Product Name | ARTG ID | Sponsor | Status | Reg. Date | Ingredient |
---|
No Australia products found for this drug